RxDoctor Payments DataLook up a doctor →

Ryan Jacobs, MD

Hematology · Charlotte, NCNPI 1114160082

Payments from drug & device makers

$8,529,245in general payments, 2019–2025

Across 1,957 payments — averaging $4358.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$1.8M
  • Eli Lilly$1.4M
  • AbbVie$1M
  • TG Therapeutics, Inc.$926K
  • AstraZeneca$701K
  • Beone Medicines Ltd.$677K
  • plus $2M from 25 others
$2,248in research payments, 2019–2025

Across 3 payments — averaging $749.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$2K

What the payments were for

  • Consulting fees$320,71421%
  • Speaking & faculty fees$1,005,25565%
  • Travel & lodging$170,07411%
  • Food & beverage$47,0413%
  • Education$210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,529,245 in reported general payments places this provider in the 95th percentile of 65 hematology providers in North Carolina.

See all hematology providers in North Carolina

Medicare billing

Part B allowed, 2024
$56,170
Medicare patients
175
Services billed
567

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate109$1,479,908
BrukinsaZanubrutinib73$926,729
ImbruvicaIbrutinib50$715,794
VenclextaVenetoclax57$571,514
Deferasirox11$6,366
Acyclovir94$1,284
Potassium Chloride25$258
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim21$173
Prednisone23$115
Ondansetron Hcl18$99
Levofloxacin11$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$700,530$1,479,908109 claims
Beigene USA, Inc.Brukinsa$189,683$926,72973 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$414,399$715,79450 claims
AbbVieVenclexta$1,008,904$571,51457 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 65 hematology providers in North Carolina.

Other hematology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →